Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Journal article published in 2019 by
D. Moro-Sibilot,
N. Cozic,
M. Pérol,
J. Mazières,
J. Otto,
P. J. Souquet,
R. Bahleda,
M. Wislez,
G. Zalcman 
,
S. D. Guibert,
F. Barlési,
B. Mennecier,
I. Monnet,
R. Sabatier,
S. Bota
and other authors.
,
S. D. Guibert,
F. Barlési,
B. Mennecier,
I. Monnet,
R. Sabatier,
S. Bota
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 